tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
RatingsHold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
12d ago
KROS
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
PremiumRatings
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
17d ago
KROS
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
PremiumThe Fly
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
17d ago
KROS
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
PremiumRatings
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
3M ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
3M ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe FlyKeros Therapeutics announces collaboration with Sean M. Healey & AMG Center
3M ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
Premium
The Fly
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
3M ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
Premium
Company Announcements
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
3M ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
PremiumThe Fly
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
3M ago
KROS
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
PremiumCompany Announcements
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
3M ago
8K
KROS
KROS Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
KROS Upcoming Earnings Report: What to Expect?
3M ago
KROS
Keros Therapeutics Adds Veteran Finance Leader to Board
PremiumCompany Announcements
Keros Therapeutics Adds Veteran Finance Leader to Board
3M ago
8K
KROS
Keros Therapeutics CEO to Present at Multiple Conferences
PremiumCompany AnnouncementsKeros Therapeutics CEO to Present at Multiple Conferences
3M ago
8K
KROS
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
Premium
Company Announcements
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
5M ago
8K
KROS
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
NNE
ABTC
Keros Therapeutics price target raised to $19 from $18 at BofA
PremiumThe Fly
Keros Therapeutics price target raised to $19 from $18 at BofA
6M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
PremiumThe Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
7M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
PremiumThe Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
7M ago
KROS
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
PremiumRatings
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
7M ago
KROS
Keros Therapeutics Reports Strong Revenue Growth
PremiumCompany AnnouncementsKeros Therapeutics Reports Strong Revenue Growth
7M ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
Premium
Ratings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
7M ago
KROS
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
Premium
Ratings
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
7M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >